Hiroshi Itoh Selected Research

HGF activator

9/2018	Aberrant methylation and silencing of the SPINT2 gene in high-grade gliomas.
2/2006	Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo.
9/2005	Diverse roles of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in the growth of glioblastoma cells in vivo.
9/2004	Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front.
2/2004	Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma.
6/2003	Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroshi Itoh Research Topics

Disease

62	Hypertension (High Blood Pressure) 04/2022 - 05/2002
45	Neoplasms (Cancer) 04/2022 - 02/2002
44	Type 2 Diabetes Mellitus (MODY) 01/2022 - 08/2003
32	Insulin Resistance 01/2021 - 07/2003
31	Inflammation (Inflammations) 03/2022 - 12/2006
26	Obesity 12/2022 - 07/2003
18	Chronic Renal Insufficiency 01/2022 - 01/2009
17	Hyperaldosteronism (Conn Syndrome) 01/2022 - 03/2002
16	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 10/2003
16	Diabetic Nephropathies (Diabetic Nephropathy) 01/2021 - 01/2007
16	Proteinuria 01/2021 - 06/2007
15	Albuminuria 10/2019 - 12/2009
13	Diabetic Retinopathy (Retinopathy, Diabetic) 05/2022 - 07/2009
13	Body Weight (Weight, Body) 03/2022 - 10/2002
13	Atherosclerosis 01/2014 - 01/2002
12	Infections 12/2022 - 06/2004
12	Chronic Kidney Failure (Chronic Renal Failure) 10/2022 - 01/2007
12	Ischemia 11/2019 - 01/2002
12	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2014 - 10/2003
11	Hyperglycemia 01/2022 - 02/2007
11	Glucose Intolerance 12/2021 - 12/2009
11	Hypoglycemia (Reactive Hypoglycemia) 03/2020 - 01/2011
10	Diabetes Mellitus 12/2022 - 07/2003
10	Hypertrophy 10/2022 - 01/2009
10	Essential Hypertension 01/2022 - 06/2008
10	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 11/2007
9	Fibrosis (Cirrhosis) 01/2022 - 07/2007
9	Adenoma (Adenomas) 11/2021 - 03/2002
9	Kidney Diseases (Kidney Disease) 01/2020 - 10/2007
8	Peritonitis 12/2022 - 01/2015
8	Hypercholesterolemia 05/2022 - 01/2013
8	Stroke (Strokes) 01/2020 - 05/2002
8	Renal Insufficiency (Renal Failure) 11/2018 - 11/2008
8	Neoplasm Metastasis (Metastasis) 11/2016 - 07/2002
7	Weight Gain 01/2021 - 01/2008
7	Hypoxia (Hypoxemia) 01/2019 - 07/2003
6	Heart Failure 12/2022 - 07/2010
6	Mitochondrial Diseases (Mitochondrial Disease) 09/2022 - 03/2008
6	Weight Loss (Weight Reduction) 01/2021 - 10/2009
6	Hypokalemia 01/2019 - 03/2002
5	Gestational Diabetes (Gestational Diabetes Mellitus) 12/2021 - 06/2010
5	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 09/2012
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 02/2004

Drug/Important Bio-Agent (IBA)

33	Glucose (Dextrose)FDA LinkGeneric 03/2022 - 01/2008
28	ReninIBA 01/2022 - 03/2002
26	Proteins (Proteins, Gene)FDA Link 10/2022 - 04/2002
26	AldosteroneIBA 04/2022 - 03/2002
20	Insulin (Novolin)FDA Link 01/2020 - 01/2008
20	Prorenin ReceptorIBA 06/2018 - 06/2007
17	LipidsIBA 05/2022 - 05/2002
16	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2022 - 05/2002
16	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2008
16	Angiotensin Receptor AntagonistsIBA 10/2020 - 03/2002
14	Antihypertensive Agents (Antihypertensives)IBA 10/2020 - 05/2002
13	Messenger RNA (mRNA)IBA 01/2022 - 09/2002
12	SaltsIBA 04/2022 - 05/2002
12	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2022 - 08/2008
12	AdiponectinIBA 01/2021 - 07/2003
12	Angiotensin IIIBA 10/2015 - 10/2003
11	CytokinesIBA 09/2017 - 04/2003
10	AlbuminsIBA 01/2021 - 01/2011
10	EnzymesIBA 01/2019 - 01/2002
10	Peptides (Polypeptides)IBA 01/2018 - 12/2005
10	AngiotensinsIBA 10/2015 - 01/2009
9	Pharmaceutical PreparationsIBA 09/2022 - 10/2008
9	VaccinesIBA 06/2022 - 09/2011
9	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 12/2002
8	oxidized low density lipoproteinIBA 12/2021 - 11/2002
8	Hormones (Hormone)IBA 12/2021 - 03/2003
8	CholesterolIBA 06/2021 - 01/2007
8	C-Reactive ProteinIBA 01/2021 - 11/2007
8	Streptozocin (Streptozotocin)FDA Link 01/2021 - 01/2008
8	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2020 - 05/2002
7	LDL CholesterolIBA 05/2022 - 03/2014
7	esaxerenoneIBA 01/2022 - 01/2019
7	Hemoglobins (Hemoglobin)IBA 06/2021 - 01/2011
7	AntigensIBA 01/2021 - 10/2007
7	Adrenocorticotropic Hormone (ACTH)FDA Link 03/2020 - 03/2002
6	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 04/2013
6	Bile Acids and Salts (Bile Acids)IBA 11/2021 - 07/2011
6	AntibodiesIBA 01/2021 - 09/2004
6	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2020 - 02/2009
6	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 11/2013
6	AdipokinesIBA 01/2019 - 07/2003
6	HGF activatorIBA 09/2018 - 06/2003
6	Transcription Factors (Transcription Factor)IBA 05/2018 - 04/2003
6	MicroRNAs (MicroRNA)IBA 06/2016 - 06/2010
5	SodiumIBA 03/2022 - 05/2010
5	NAD (NADH)IBA 01/2022 - 11/2002
5	Sirtuin 1IBA 01/2022 - 04/2010
5	SteroidsIBA 12/2021 - 02/2009
5	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 12/2019 - 10/2008

Therapy/Procedure

77	Therapeutics 12/2022 - 04/2002
15	Renal Dialysis (Hemodialysis) 12/2022 - 01/2007
12	Peritoneal Dialysis 12/2022 - 09/2011
9	Glycemic Control 02/2019 - 01/2012
8	Drug Therapy (Chemotherapy) 04/2022 - 02/2005
8	Adrenalectomy 11/2021 - 01/2016
7	Catheters 12/2022 - 07/2005
6	Radiotherapy 04/2022 - 07/2002